Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adaptive Biotechnologies Corp
(NQ:
ADPT
)
4.700
+0.030 (+0.64%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adaptive Biotechnologies Corp
< Previous
1
2
Next >
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
April 06, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
February 27, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
February 14, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
January 23, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
December 10, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
December 05, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
December 01, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
November 21, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
November 21, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
October 11, 2022
Integration with the most widely used comprehensive electronic health record will expand clinician and patient access to clonoSEQ
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
October 05, 2022
From
Adaptive Biotechnologies
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.